Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor | Department of Applied Biology and Chemical Technology | en_US |
| dc.contributor.advisor | Chow, Ming-cheung Larry (ABCT) | - |
| dc.creator | Chong, Tsz Cheung | - |
| dc.identifier.uri | https://theses.lib.polyu.edu.hk/handle/200/9594 | - |
| dc.language | English | en_US |
| dc.publisher | Hong Kong Polytechnic University | - |
| dc.rights | All rights reserved | en_US |
| dc.title | Characterization of novel flavonoid dimers as breast cancer resistance protein (BCRP)-modulators | en_US |
| dcterms.abstract | Cancer causes many deaths each year. A lot of anticancer drugs have been developed and some of them give promising results. Nevertheless, some patients become unresponsive to chemotherapy after prolonged treatment and develop multidrug resistance (MDR). Some MDR cases are caused by overexpression of ATP Binding Cassette (ABC) transporter ABCG2/BCRP. Inhibition of BCRP-mediated drug efflux could be one of the possible solutions to tackle MDR. Previously, flavonoid dimers have been shown to reverse ABCB1-mediated drug resistance. In view of the promising reversal potential of flavonoid dimers, a click chemistry approach was developed to generate a library of novel flavonoid dimers to discover new BCRP modulators. Click chemistry allowed rapid synthesis of a large combinations of triazole-containing homodimers and heterodimers of flavonoids. Screening resulted in the identification of FD 15_8 as a potent BCRP modulator. Its EC50s were 1.3±0.7nM in reversing topotecan resistance in BCRP-overexpressing MCF7/MX100 cells and 70.4±17.1nM in S1M180 cells. FD 15_8 increased intracellular level of topotecan and doxorubicin in BCRP-expressing cells. It did not affect BCRP protein expression level, nor cellular localization of BCRP. Instead FD15_8 inhibited BCRP-ATPase activity. Lineweaver-Burk and Dixon analysis suggested that FD 15_8 was a non-competitive inhibitor for BCRP in a mixed mode of inhibition. Intraperitoneal administration of FD 15_8 resulted in the best pharmacokinetics profile in mice with plasma level maintained above its EC₅₀ level for more than 10 hours. Co-administration of FD 15_8 at 45 mg/kg with topotecan at 2 mg/kg can suppress the S1M180 tumor volume by 40.3% after 24 times of treatment for once every two days. Administration FD 15_8 alone or topotecan did not result in severe toxicity. No death incidence recorded during the combination of 45 mg/kg FD 15_8 and 2mg/kg topotecan combination group. In conclusion, FD 15_8 is a safe and potent BCRP modulator. | en_US |
| dcterms.extent | ix, 117 pages : color illustrations | en_US |
| dcterms.isPartOf | PolyU Electronic Theses | en_US |
| dcterms.issued | 2018 | en_US |
| dcterms.educationalLevel | Ph.D. | en_US |
| dcterms.educationalLevel | All Doctorate | en_US |
| dcterms.LCSH | Hong Kong Polytechnic University -- Dissertations | en_US |
| dcterms.LCSH | Drug resistance in cancer cells | en_US |
| dcterms.LCSH | Multidrug resistance | en_US |
| dcterms.accessRights | open access | en_US |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 991022164558203411.pdf | For All Users | 3.69 MB | Adobe PDF | View/Open |
Copyright Undertaking
As a bona fide Library user, I declare that:
- I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
- I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
- I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.
By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.
Please use this identifier to cite or link to this item:
https://theses.lib.polyu.edu.hk/handle/200/9594